DE60037192D1 - Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens - Google Patents

Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens

Info

Publication number
DE60037192D1
DE60037192D1 DE60037192T DE60037192T DE60037192D1 DE 60037192 D1 DE60037192 D1 DE 60037192D1 DE 60037192 T DE60037192 T DE 60037192T DE 60037192 T DE60037192 T DE 60037192T DE 60037192 D1 DE60037192 D1 DE 60037192D1
Authority
DE
Germany
Prior art keywords
medicine
progress
prevent
cerebral blood
blood disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60037192T
Other languages
English (en)
Other versions
DE60037192T2 (de
Inventor
Mami Ojima
Takahito Kitayoshi
Masaomi Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE60037192D1 publication Critical patent/DE60037192D1/de
Application granted granted Critical
Publication of DE60037192T2 publication Critical patent/DE60037192T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60037192T 1999-07-21 2000-07-19 Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens Expired - Lifetime DE60037192T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20587799 1999-07-21
JP20587799 1999-07-21
PCT/JP2000/004830 WO2001005428A1 (fr) 1999-07-21 2000-07-19 Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution

Publications (2)

Publication Number Publication Date
DE60037192D1 true DE60037192D1 (de) 2008-01-03
DE60037192T2 DE60037192T2 (de) 2008-05-15

Family

ID=16514222

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60037192T Expired - Lifetime DE60037192T2 (de) 1999-07-21 2000-07-19 Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens

Country Status (7)

Country Link
US (3) US6852743B1 (de)
EP (2) EP1197226B1 (de)
JP (1) JP2001089393A (de)
AU (1) AU6019700A (de)
CA (1) CA2379666C (de)
DE (1) DE60037192T2 (de)
WO (1) WO2001005428A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005428A1 (fr) * 1999-07-21 2001-01-25 Takeda Chemical Industries, Ltd. Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
US20040097565A1 (en) * 2001-01-29 2004-05-20 Terashita Zen-Ichi Analgesic and antiinflammatory drugs
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
AU2002364381A1 (en) * 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
EP1452176A4 (de) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Mittel zur verbesserung der insulinresistenz
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
JP5100039B2 (ja) * 2003-01-31 2012-12-19 第一三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
CN1798557A (zh) * 2003-05-29 2006-07-05 协和梅迪克斯株式会社 抗抑郁剂或者抗抑郁用饮食品
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
KR20130135994A (ko) * 2005-06-27 2013-12-11 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
US9066936B2 (en) * 2007-03-28 2015-06-30 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) * 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB9110636D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4219534A1 (de) * 1992-02-19 1993-12-16 Thomae Gmbh Dr K Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
US6177587B1 (en) 1997-05-26 2001-01-23 Takeda Chemical Industries, Ltd. Production method of aminobenzene compound
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
PT1096932E (pt) * 1998-07-10 2007-09-21 Novartis Pharma Ag ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio''
FR2783422A1 (fr) * 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
WO2001005428A1 (fr) * 1999-07-21 2001-01-25 Takeda Chemical Industries, Ltd. Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen

Also Published As

Publication number Publication date
EP1197226A4 (de) 2003-01-07
WO2001005428A1 (fr) 2001-01-25
US6852743B1 (en) 2005-02-08
EP1867342A1 (de) 2007-12-19
US20050096382A1 (en) 2005-05-05
CA2379666C (en) 2009-10-13
EP1197226B1 (de) 2007-11-21
US20100120800A1 (en) 2010-05-13
CA2379666A1 (en) 2001-01-25
EP1197226A1 (de) 2002-04-17
JP2001089393A (ja) 2001-04-03
AU6019700A (en) 2001-02-05
DE60037192T2 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DE60037192D1 (de) Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens
EP1231864A4 (de) Am gewebe befestigbarer medikamentenverabreichungskatheter und methode zu deren anwendung
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
NO20003051D0 (no) Metode for administrering av AspB28-humant insulin
PL1641918T3 (pl) Komórki poporodowe do zastosowania w leczeniu choroby serca i układu krążenia
BR9707489A (pt) Composto composição farmacêutica e processo para tratar um paciente sofrendo de um distúrbio fisilógico
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
EE05067B1 (et) Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
ATE456954T1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
EP1187604A4 (de) Verbindungen und methoden zur behandlung von störungen duch post-traumatischen stress
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
EP1114862A3 (de) Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
BR9510015A (pt) Composto composição farmacéutica e processo para o tratamento de doenças enfecciosas em terapia humana ou veterinária
FR2799650B1 (fr) Procede pour limiter la penetration dans la peau et/ou les fibres keratiniques d'un agent cosmetique et/ou pharmaceutique actif
DE60142584D1 (de) Multilumen katheter und implantate zur verabreichung von therapeutischen substanzen an gewebe
NO20000376D0 (no) Transdermalt terapeutisk system for frigiving av virkestoff gjennom huden inn i en organisme og fremgangsmåte for påfoering på huden
GB0312566D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
GB9908059D0 (en) Diagnosis and treatment of diseases
WO2001019359A3 (en) Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
EE200200348A (et) Ravimkoostis kasutamiseks valu ravis
ATE309793T1 (de) Superfizielles therapeutisches system zur topischen applikation von acetylsalicylsäure zur behandlung von akne-erkrankungen
EP1420776A4 (de) Arzneimittel zur behandlung von hirnverletzungen und anwendungsverfahren dafür
ITMI992566A0 (it) Composizione dermatologica per il trattamento topico di malattie cutan ee

Legal Events

Date Code Title Description
8364 No opposition during term of opposition